Compare Keysight Technologies Inc (KEYS) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Keysight Technologies Inc vs BIO-TECHNE Corp — how do they compare? Keysight Technologies Inc trades at $341.48 (market cap $57.32B), while BIO-TECHNE Corp trades at $72.12 (market cap $11.24B). The key difference: Keysight Technologies Inc is far larger — about 5.1× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Keysight Technologies Inc pays none. Which is the better fit depends on your goals.
| KEYS | TECH | |
|---|---|---|
Market Cap | $57.32B | $11.24B |
Sector | Technology | Health |
52-Week High | $373.34 | $72.29 |
52-Week Low | $158.51 | $43.31 |
Enterprise Value | $57.67B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Keysight Technologies (KEYS) trades at $340.97, up 1.19% today, near its 52-week high. The stock shows strong momentum with bullish moving averages and consistent earnings beats, including Q1 2026 EPS of $2.87 versus $2.32 expected. Revenue for 2025 reached $5.38B with a net income margin of 17.31%. Recent news highlights product innovations like the APS-ONE-400 cybersecurity platform and collaborations with Intel and the European Space Agency, reinforcing growth prospects in 5G and defense markets.
Outlook remains positive with a consensus price target of $396.56, implying 16% upside, supported by 81% analyst buy ratings. Risks include elevated valuation multiples (P/E 54.91) and high RSI levels suggesting overbought conditions. Investors should monitor execution on 2026 revenue guidance of $6.1B and manage exposure to tech sector volatility.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
